AU6576398A - Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus - Google Patents

Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus

Info

Publication number
AU6576398A
AU6576398A AU65763/98A AU6576398A AU6576398A AU 6576398 A AU6576398 A AU 6576398A AU 65763/98 A AU65763/98 A AU 65763/98A AU 6576398 A AU6576398 A AU 6576398A AU 6576398 A AU6576398 A AU 6576398A
Authority
AU
Australia
Prior art keywords
tetrahydro
benzoic acid
tetramethyl
naphthyloxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU65763/98A
Other languages
English (en)
Inventor
Andrea Fanjul
Waldemar Lernhardt
Magnus Pfahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Publication of AU6576398A publication Critical patent/AU6576398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Physical Vapour Deposition (AREA)
AU65763/98A 1997-03-24 1998-03-24 Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus Abandoned AU6576398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3560497P 1997-03-24 1997-03-24
US60035604 1997-03-24
PCT/US1998/005591 WO1998042340A1 (en) 1997-03-24 1998-03-24 Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus

Publications (1)

Publication Number Publication Date
AU6576398A true AU6576398A (en) 1998-10-20

Family

ID=21883695

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65763/98A Abandoned AU6576398A (en) 1997-03-24 1998-03-24 Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus

Country Status (11)

Country Link
EP (1) EP1019049A1 (pt)
JP (1) JP2001521551A (pt)
KR (1) KR20010005678A (pt)
CN (1) CN1256630A (pt)
AU (1) AU6576398A (pt)
BR (1) BR9808054A (pt)
CA (1) CA2284192A1 (pt)
IL (1) IL132032A0 (pt)
NO (1) NO994612L (pt)
NZ (1) NZ337927A (pt)
WO (1) WO1998042340A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR023700A1 (es) * 1998-11-12 2002-09-04 Smithkline Beecham Plc Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina
KR100643833B1 (ko) * 1998-11-12 2006-11-10 스미스클라인비이참피이엘시이 인슐린 감작제 및 다른 항당뇨병 약제의 개선된 방출을위한 제약 조성물
WO2002100396A1 (en) * 2001-06-07 2002-12-19 Wyeth COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT
CN1921843A (zh) * 2004-01-23 2007-02-28 独立行政法人科学技术振兴机构 含视黄酸的糖尿病治疗药
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
CA2937107C (en) 2014-01-17 2020-12-22 Cornell University Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504847A (ja) * 1989-03-08 1992-08-27 ザ ユニバーシティ オヴ バージニア パテント ファウンデーション インスリン抵抗性糖尿病のための食事用補添物
FR2695317B1 (fr) * 1992-09-07 1995-03-10 Monal Lab Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
AU676227B2 (en) * 1993-01-22 1997-03-06 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5444086A (en) * 1994-03-31 1995-08-22 American Home Products Corporation Naphthalenylmethyl thiophenones as antihyperglycemic agents

Also Published As

Publication number Publication date
WO1998042340A1 (en) 1998-10-01
JP2001521551A (ja) 2001-11-06
CA2284192A1 (en) 1998-10-01
NO994612L (no) 1999-11-24
NZ337927A (en) 2000-11-24
KR20010005678A (ko) 2001-01-15
BR9808054A (pt) 2000-11-07
CN1256630A (zh) 2000-06-14
IL132032A0 (en) 2001-03-19
NO994612D0 (no) 1999-09-22
EP1019049A1 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
US6028052A (en) Treating NIDDM with RXR agonists
EP0859608B1 (en) Treating niddm with rxr agonists
AU678291B2 (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
Spencer et al. Troglitazone
DE60124861T2 (de) Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
CA2213690A1 (fr) Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
EP1142870A1 (en) Novel ligands of nuclear receptor
AU6576398A (en) Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
WO1998042340A9 (en) Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
WO2007007757A1 (ja) PPARγアゴニストを含有する医薬組成物
US20040152746A1 (en) Treatment of scarring and related conditions using ppar-gamma activators
EP1637161A1 (en) REMEDY FOR CEREBRAL NEURODEGENERATIVE DISEASES USING PPAR&dgr; AGONIST
WO2005079792A1 (ja) 重症糖尿病網膜症の予防又は治療剤
KR20010012556A (ko) 다낭포성 난소 증후군 및 임신성 당뇨병의 치료에 있어서5-(4-(2-(n-메틸-n-(2-피리딜)아미노)-에톡시)벤질)2,4-티아졸리딘디온의 용도
MXPA99008765A (en) Methods and compositions for treating and/or preventing non-insulin dependent diabetes mellitus (niddm) using specific retinoid compounds
Sorbera et al. Netoglitazone
US6046202A (en) Use of thiazolidinedione derivatives in the treatment of insulin resistance
JP2005514399A (ja) PPARγアクチベーターの投薬法
JP3007683B2 (ja) 新規な医薬用途
Wang Focus on repaglinide: an oral hypoglycemic agent with a more rapid onset and shorter duration of action than the sulfonylureas
US20020019344A1 (en) Methods of preventing allograft rejection
RU2191007C2 (ru) Способ лечения иhcд агонистами rxr
CA2232288C (en) Treating niddm with rxr agonists
MXPA98002104A (en) Compositions using a rxr agonist only or in combination with a ppar agonist, to treat diabetes mellitus not dependent on insul
NL8402850A (nl) Werkwijze voor de behandeling van psychomotorische spanning, middel voor een dergelijke behandeling, alsmede farmaceutisch preparaat voor een dergelijke behandeling.

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted